The current therapeutic landscape of hemophilia in the United States is driven by several approved therapies. The hemophilia market is estimated to grow for the period 2019-2032. The major reason behind the hemophilia market upsurge is the launch of the most anticipated gene therapies,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.